
|Videos|January 14, 2015
Important Considerations in Iron Chelation Therapy
Advertisement
Episodes in this series

Any patient receiving regular blood transfusions will need to have the excess iron in their body removed, says Thomas D. Coates, MD. For patients who receive iron chelation therapy, careful monitoring is critical, as renal and neurologic side effects can occur. Iron chelation therapy can also result in low white blood cell counts, adds Coates. In children, it is important to recognize that iron is essential to their growth and development.
In Coates’ opinion, regulating the dose of an iron chelating agent should be based more on tolerance for the medication than on the body’s iron levels. Poor adherence remains an issue with these agents, adds Coates.
Advertisement
Related to this article

The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5

























